Zacks Investment Research upgraded shares of POXEL (OTCMKTS:PXXLF) from a hold rating to a buy rating in a research report report published on Tuesday, January 16th. Zacks Investment Research currently has $6.00 price target on the stock.
According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “
Shares of POXEL (PXXLF) remained flat at $$5.35 during trading on Tuesday.
COPYRIGHT VIOLATION NOTICE: “POXEL (OTCMKTS:PXXLF) Stock Rating Upgraded by Zacks Investment Research” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2018/02/12/poxel-pxxlf-raised-to-buy-at-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for POXEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POXEL and related companies with MarketBeat.com's FREE daily email newsletter.